We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-18.45%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$313M
AUM Growth
-$175M
Cap. Flow
-$57.5M
Cap. Flow %
-18.35%
Top 10 Hldgs %
88.94%
Holding
23
New
1
Increased
–
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SNTI icon
Senti Biosciences Holdings
SNTI
+$1.57M

Top Sells

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$33.6M
2
GOSS icon
Gossamer Bio
GOSS
+$12.9M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.28M
4
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$4.26M
5
ICVX
Icosavax, Inc. Common Stock
ICVX
+$3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.42%
2 Financials 1.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$81.7M 26.07%
4,673,380
– –
NUVB icon
2
Nuvation Bio
NUVB
$2.24B
$49.4M 15.77%
15,247,340
-7,710,000
-34% -$33.6M
IMGO
3
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$40.4M 12.9%
3,018,737
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$21.9M 7%
1,010,769
-189,245
-16% -$5.28M
CINC
5
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$18.2M 5.81%
966,176
– –
ALPN
6
DELISTED
Alpine Immune Sciences Inc
ALPN
$17.3M 5.51%
2,029,580
– –
KRON
7
DELISTED
Kronos Bio
KRON
$13.9M 4.44%
3,818,283
– –
ARQT icon
8
Arcutis Biotherapeutics
ARQT
$3.42B
$13.3M 4.24%
623,836
– –
GOSS icon
9
Gossamer Bio
GOSS
$66.5M
$12.6M 4.01%
1,500,000
-1,664,835
-53% -$12.9M
IMA
10
ImageneBio Inc
IMA
$63.1M
$9.96M 3.18%
187,427
– –
IMUX icon
11
Immunic
IMUX
$182M
$6.21M 1.98%
178,816
– –
SANA icon
12
Sana Biotechnology
SANA
$885M
$5.42M 1.73%
843,750
– –
OMEG
13
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.93M 1.58%
501,000
– –
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.93M 1.26%
711,479
– –
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.8M 1.21%
1,971,241
– –
SPRB
16
Spruce Biosciences
SPRB
$119M
$3.76M 1.2%
28,814
– –
SYRS
17
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.42M 0.77%
251,271
– –
IMCR icon
18
Immunocore
IMCR
$1.78B
$1.92M 0.61%
51,535
– –
EPIX
19
DELISTED
ESSA Pharma
EPIX
$1.03M 0.33%
328,196
– –
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$835K 0.27%
275,513
– –
SNTI icon
21
Senti Biosciences Holdings
SNTI
$12.6M
$386K 0.12%
+19,579
New +$1.57M
ICVX
22
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-426,395
Closed -$3M
CMPI
23
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-1,335,050
Closed -$4.26M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2022 Portfolio in Review

As of Q2 2022, Omega Fund Management held 23 positions worth $313M, down 36% from $489M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Omega Fund Management withdrew a net $57.5M in Q2 2022, closing 2 positions and reducing 3 holdings. Its most notable exit was Checkmate Pharmaceuticals, Inc. Common Stock, an estimated $4.26M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Omega Fund Management opened a new position in Senti Biosciences Holdings worth $386K.

  • Omega Fund Management's largest Q2 2022 buy was Senti Biosciences Holdings: 19,579 shares worth $386K.
  • Omega Fund Management's biggest Q2 2022 reduction was Nuvation Bio, cutting an estimated $33.6M.
  • Omega Fund Management fully exited Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $4.26M.
  • Omega Fund Management's ten largest holdings make up 89% of its $313M portfolio in Q2 2022.
  • Omega Fund Management opened 1 new position and closed 2 in Q2 2022.
  • Omega Fund Management's portfolio value fell 36% quarter-over-quarter to $313M.

Based on Omega Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.